Neurogene Reports Second Quarter 2024 Financial Results and Highlights Recent Updates Business Wire Aug 9, 2024 11:30am
Neurogene Announces RMAT Designation for NGN-401 Investigational Gene Therapy for Rett Syndrome Business Wire Aug 7, 2024 11:30am